What Psychedelics Are Legal in Australia? A Guide to Therapeutic Access

Australia’s approach to psychedelics has undergone a historic transformation since July 2023. The Therapeutic Goods Administration (TGA) now permits the use of MDMA and psilocybin for specific mental health conditions, making Australia the first country to legalise psychedelic-assisted therapy within a national healthcare framework. Nevertheless, legal access is strictly controlled and available only through authorised psychiatrists. Consequently, understanding exactly which psychedelics are legal, under what conditions, and through what pathways is essential for patients and practitioners alike.

The Two Legal Psychedelics: MDMA and Psilocybin

Currently, only two psychedelic substances are legally available for therapeutic use in Australia:

• MDMA (3,4-methylenedioxy-methamphetamine): Legal for treating Post-Traumatic Stress Disorder (PTSD)
• Psilocybin: The active compound in “magic mushrooms,” legal for Treatment-Resistant Depression (TRD)

For these specific uses, MDMA and psilocybin are classified as Schedule 8 (Controlled Drugs) medicines in the Poisons Standard. For all other indications, they remain Schedule 9 (Prohibited Substances), limiting their use to medical and scientific research. Furthermore, other psychedelics like LSD, DMT, and mescaline remain entirely prohibited for any use.

The Therapeutic Exception: A Narrow Pathway

The legal access is not a general approval but a narrow, condition-specific exception. MDMA and psilocybin are “unapproved” therapeutic goods, meaning they are not included in the Australian Register of Therapeutic Goods (ARTG) and have not been evaluated by the TGA for safety, quality, or efficacy. Consequently, they can only be accessed through two regulated pathways:

1. The Authorised Prescriber (AP) Scheme

Only psychiatrists registered with the Australian Health Practitioner Regulation Agency (AHPRA) and Fellows of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) can prescribe these substances. To become an Authorised Prescriber, psychiatrists must:

• Develop a clinical treatment protocol aligned with published studies
• Obtain approval from a registered Human Research Ethics Committee (HREC)
• Receive authorisation from the TGA under the AP scheme

Once authorised, psychiatrists can prescribe these substances as part of Psychedelic-Assisted Psychotherapy (PAP) in a medically supervised setting. The AP psychiatrist must be present in-person while the psychedelic is being administered. Patients cannot take these medicines home.

2. Clinical Trials

MDMA and psilocybin can also be accessed through participation in regulated clinical trials. Researchers must obtain approval from an HREC and the TGA to conduct these studies.

What This Means for Patients

For eligible patients, the path forward is clear but narrow. You cannot simply visit a doctor or clinic to obtain a prescription for these substances. Instead, the process involves:

1. Discussion with a General Practitioner: Your GP can assess your condition and refer you to a suitable psychiatrist who is or can become an Authorised Prescriber.
2. Psychiatrist Assessment: The authorised psychiatrist will evaluate whether you meet the eligibility criteria for MDMA or psilocybin treatment.
3. Treatment in a Controlled Setting: Treatment occurs in a medically supervised healthcare setting with good clinical governance practices, established administration and patient monitoring procedures.

Conclusion

Australia’s legal psychedelic framework is pioneering but highly restricted. Only MDMA and psilocybin are legal, and only for PTSD and TRD respectively, under the care of authorised psychiatrists. Other psychedelics remain illegal, and even the legal substances cannot be obtained outside the strict therapeutic pathway. For patients with treatment-resistant conditions who have exhausted other options, discussing these treatments with a psychiatrist who is or can become an Authorised Prescriber is the only legal path forward.